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Bacterial attenuation is typically thought of as reduced bacterial growth in the presence of constant immune pressure. Infection
with Francisella tularensis elicits innate and adaptive immune responses. Several in vivo screens have identified F. tularensis
genes necessary for virulence. Many of these mutations render F. tularensis defective for intracellular growth. However, some
mutations have no impact on intracellular growth, leading us to hypothesize that these F. tularensis mutants are attenuated be-
cause they induce an altered host immune response. We were particularly interested in the F. tularensis LVS (live vaccine strain)
clpB (FTL_0094) mutant because this strain was attenuated in pneumonic tularemia yet induced a protective immune response.
The attenuation of LVS clpB was not due to an intracellular growth defect, as LVS clpB grew similarly to LVS in primary bone
marrow-derived macrophages and a variety of cell lines. We therefore determined whether LVS clpB induced an altered immune
response compared to that induced by LVS in vivo. We found that LVS clpB induced proinflammatory cytokine production in
the lung early after infection, a process not observed during LVS infection. LVS clpB provoked a robust adaptive immune re-
sponse similar in magnitude to that provoked by LVS but with increased gamma interferon (IFN-) and interleukin-17A (IL-
17A) production, as measured by mean fluorescence intensity. Altogether, our results indicate that LVS clpB is attenuated due to
altered host immunity and not an intrinsic growth defect. These results also indicate that disruption of a nonessential gene(s)
that is involved in bacterial immune evasion, like F. tularensis clpB, can serve as a model for the rational design of attenuated
vaccines.
Enormous efforts have gone into detecting bacterial mutationsthat result in diminished growth in vivo. Many of these muta-
tions are the result of a failure of the pathogen to grow in vitro and
can be attributed to defects in critical aspects of bacterial metab-
olism. Mutations, for example, that result in auxotrophy render
the bacteria incapable of synthesizing essential nutrients such as
purines or coenzymes and therefore cause a growth defect. Rela-
tively few mutations that cause bacterial attenuation have been
demonstrated to be the result of a failure of the pathogen to inter-
fere with host immune responses. In this article, we focus on one
mutation that likely falls into this class of altered host immunity.
Francisella tularensis is a Gram-negative coccobacillus and
the causative agent of the zoonotic disease tularemia. Inhala-
tion of as few as 10 virulent type A F. tularensis organisms can
cause fatal disease in humans (1). This low infectious dose, the
ability to persist in the environment, the ease of aerosolization,
and the high morbidity and mortality have earned F. tularensis
a category A select agent classification (2). In fact, F. tularensis
has been used as the infectious agent in bioweapons and con-
tinues to present a real threat today (3, 4). It is therefore critical
to understand both infection and pathogenesis. Many attenu-
ating mutations of Francisella have been described (5–7), but
little information is available on the immune response to at-
tenuated mutants, beyond whether they can protect from sec-
ondary challenge with wild-type bacteria.
Experiments utilizing F. tularensis as the infectious agent typi-
cally use three strains that differ widely for virulence in humans
and mice. F. tularensis subsp. tularensis SchuS4 is a type A strain
and must be handled under biosafety level 3 (BSL-3) conditions
because of its low infectious dose and its ability to be transmitted
via aerosol. SchuS4 is highly pathogenic in mice, with a 100%
lethal dose (LD100) of 10 CFU (8). Mice inoculated with SchuS4
succumb to infection within 6 days of inoculation (9), making
studies of the adaptive immune response in nonmanipulated mice
impossible. For our experiments, we used the type B strain F.
tularensis subsp. holarctica LVS (live vaccine strain). LVS is atten-
uated in humans and mice compared to SchuS4. Although LVS
was widely used in eastern Europe as a vaccine, it is unlikely to ever
be licensed in the United States. The intranasal LD50 of LVS is
approximately 1,000 CFU in mice (8), allowing us to examine
aspects of adaptive immunity using an intranasal inoculation dose
of 500 CFU. The third strain commonly used is Francisella novi-
cida U112, which is avirulent in immunocompetent humans but is
highly virulent in mice, with a low infectious dose and rapid death,
similar to SchuS4.
The immune response to F. tularensis is multilayered and com-
plex, requiring components of both innate and adaptive immu-
nity. The bacterium has evolved several strategies to evade or sub-
vert the host’s immune response so that it can persist in the host.
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First, F. tularensis infects a variety of innate immune cells during
infection in the lung, including macrophages, dendritic cells,
monocytes, and neutrophils (10, 11). F. tularensis also expresses a
form of lipopolysaccharide (LPS) that does not efficiently stimu-
late Toll-like receptor 4 (TLR4) (12). LVS does not stimulate func-
tional maturation (cytokine production) of dendritic cells but
does promote phenotypic maturation through the upregulation
of CD80 and CD86 (11). SchuS4 does not induce phenotypic or
functional maturation of dendritic cells, allowing the bacterium to
persist in an immunosuppressed environment (13). Finally, F.
tularensis lives intracellularly, allowing the bacterium to avoid an-
tibody- and complement-mediated destruction (14).
Because F. tularensis replicates within host cells, the T cell re-
sponse is a critical component for bacterial clearance. Indeed, T
cells are required for clearance of F. tularensis and the develop-
ment of protective immunity (15). In particular, gamma inter-
feron (IFN-) is required for controlling F. tularensis infection.
When IFN- is blocked by antibody, there is an increase in the
bacterial burden, and mice deficient in IFN- succumb to an LVS
inoculum dose that is sublethal in wild-type mice (16, 17). Ad-
ministration of recombinant IFN- to infected mice decreases
bacterial burdens, confirming this cytokine’s importance in the
control of the infection (18). Th17 cells are also induced in the
lung following intranasal inoculation (19). Interleukin-17A (IL-
17A)-deficient mice have increased bacterial burdens compared
to those in wild-type mice, and administration of IL-17-neutral-
izing antibody also increased bacterial burdens, highlighting this
cytokine’s importance during respiratory tularemia (20, 21).
Several in vivo screens have identified F. tularensis virulence
determinants in U112, LVS, and SchuS4 (5–7). A F. tularensis
mutant could be attenuated if the mutation disrupts expression of
a gene necessary for intracellular growth, such as the genes within
the pathogenicity island (22). A F. tularensis mutant could also be
attenuated if the disrupted gene causes the strain to become an
auxotroph (5–7). When a mutation does not cause an intracellular
growth defect, a strain’s attenuation could be the result of a failure
to evade the host’s immune response. We were interested in char-
acterizing the immune response to an attenuated LVS mutant,
LVS clpB (FTL_0094). clpB encodes a highly conserved chaperone
protein of the AAA superfamily of ATPases. F. tularensis ClpB is
involved in the response to oxidative, ethanol, and acid stresses
(23). LVS clpB and SchuS4 clpB strains are attenuated when deliv-
ered by intradermal, intraperitoneal, or oral inoculation routes
(23–25). Previous infection with LVS clpB and SchuS4 clpB pro-
vided protection during wild-type challenge (23–25). However,
the host’s primary immune response to LVS clpB that elicits pro-
tection during wild-type challenge has not yet been examined.
In this study, we examined the innate and adaptive immune
response following intranasal infection with LVS or LVS clpB. Our
LVS clpB strain did not show any defects in intracellular growth in
primary bone marrow-derived macrophages (BMDMs) or several
cell lines. Because there were no differences in growth, we hypoth-
esized that the attenuation of LVS clpB was due to an altered im-
mune response. Indeed, LVS clpB induced altered innate and
adaptive immune responses compared to those induced by LVS.
Other groups have shown that SchuS4 clpB and LVS clpB are at-
tenuated in vivo, but the potential mechanism(s) causing attenu-
ation has not been described (23–25). The work presented here
describes the immune response that contributes to the attenua-
tion of LVS clpB. The studies also highlight the potential use of
clpB as a target for attenuation because milder disease is caused
while still inducing a robust protective immune response in the
lung.
MATERIALS AND METHODS
Bacteria. The live vaccine strain of Francisella tularensis subsp. holarctica
(LVS) was obtained from the CDC (Atlanta, GA). F. tularensis subsp.
tularensis (SchuS4) was obtained from BEI Resources (Manassas, VA).
Bacteria were grown on chocolate agar supplemented with 1% IsoVitalex
(Becton, Dickinson), brain heart infusion (BHI) broth supplemented
with 1% IsoVitalex, or Chamberlain’s defined medium (CDM) (26).
When necessary, kanamycin (10 g/ml) or hygromycin (200 g/ml) was
added for antibiotic selection. Bacteria were grown at 37°C. To prepare
bacterial inocula, bacteria were removed from a lawn grown on chocolate
agar and resuspended in sterile phosphate-buffered saline (PBS) at an
optical density at 600 nm (OD600) of 1 (equivalent to 1  10
10 CFU/ml).
Appropriate dilutions were made in sterile PBS to obtain the desired bac-
terial dose. The number of viable bacteria was quantified by serial dilution
and plating onto chocolate agar. The LVS clpB::Tn strain was generated by
using the EZ-Tn5 system (Epicentre). The insertion in clpB mapped to
nucleotide 89763. The LVS clpB (FTL_0094) and LVS dotU (FTL_0119)
deletion strains were generated by using the suicide vector pMP812 (27)
containing an amplified region of clpB or dotU.
Bacterial growth curves. In a 96-well plate, CDM or BHI broth was
inoculated with LVS, LVS clpB, or LVS dotU so that the starting OD600 was
0.01. The OD600 was measured every 15 min for 48 h by using a Tecan
Infinite M200 plate reader capable of maintaining 37°C and 5% CO2 while
shaking.
Mice. C57BL/6J (B6), B6.SJL-PtprcaPepcb/BoyJ (B6-CD45.1), and
BALB/cByJ (BALB/c) mice were obtained from The Jackson Laboratory
(Bar Harbor, ME). B6.129S7-Rag1tm1Mom/J (Rag/) mice were pur-
chased from The Jackson Laboratory and then bred in-house. All mice
were housed under specific-pathogen-free conditions at the University of
Arizona or Duke University in accordance with their respective Institu-
tional Animal Care and Use Committees. Female B6 and BALB/c mice
used for infections were between 7 and 12 weeks of age.
Cell lines and BMDM generation. J774.1, MH-S, and A549 cells were
obtained from the ATCC (Manassas, VA). J774.1 and A549 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (Atlas), L-glutamine (HyClone), sodium
pyruvate (HyClone), and penicillin-streptomycin (Life). MH-S cells were
cultured in RPMI 1640 supplemented with 10% fetal bovine serum (At-
las), L-glutamine (HyClone), sodium pyruvate (HyClone), and penicillin-
streptomycin (Life). Medium was replaced with antibiotic-free medium
24 h prior to inoculation with F. tularensis. BMDMs were generated from
B6 bone marrow as previously described (28).
In vitro growth assays. A total of 1  106 cells/well (BMDM, J774, and
MH-S) or 0.5  106 cells/well (A549) were seeded into a 24-well plate for
intracellular growth assays and given 2 h to adhere to the plate. Cells were
inoculated at a multiplicity of infection (MOI) of 25:1. Infection was
facilitated by centrifugation at 300  g for 5 min. Cells were inoculated for
2 h with bacteria, and the medium was then removed. Medium containing
50 g/ml gentamicin (Sigma) was added to kill extracellular bacteria. One
hour after gentamicin addition, medium was removed, and the cells were
washed twice before the addition of fresh medium. To determine intra-
cellular growth, medium was removed at 4 or 24 h postinfection, and 1 ml
of PBS was added to the cells. Cells were removed from the plate by
scraping and pipetting vigorously up and down. Cells were lysed by vor-
texing at maximal speed for 1 min. Serial 1:10 dilutions of the lysate were
made and plated onto chocolate agar. The resulting colonies were counted
72 h later.
Inoculation of mice. Mice were anesthetized with 575 mg/kg of body
weight of tribromomethanol (Avertin; Sigma) administered intraperito-
neally. Mice were then intranasally inoculated with 5  102 CFU LVS, 5 
104 CFU LVS clpB, or 5  105 CFU LVS dotU suspended in 50 l PBS. For
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high-dose LVS challenge experiments, mice were anesthetized with 0.25
ml of a cocktail of 7.5 mg/ml ketamine and 0.5 mg/ml xylazine in PBS.
Mice were then intranasally inoculated with 5  103 CFU LVS. For
SchuS4 challenge, approximately 30 CFU of SchuS4 were administered
via the aerosol route in a BSL-3 chamber. Mice were weighed daily follow-
ing all inoculations. Mice were sacrificed if they lost more than 25% of
their starting weight, as indicated in the University of Arizona and Duke
IACUC protocols.
Determination of bacterial burdens. Spleens, livers, and lungs were
homogenized in sterile PBS by using a Biojector (Bioject). Tenfold serial
dilutions were made and plated onto chocolate agar. The resulting colo-
nies were counted 72 h later. The limit of detection was 50 CFU per organ.
Collection of bronchoalveolar lavage fluid. Mice were sacrificed, and
the trachea was exposed. A 22-gauge catheter was inserted into the trachea
and secured with a suture. The lungs were fully inflated with 800 l of PBS
and washed three times. Cells were removed from the bronchoalveolar
lavage fluid (BALF) by centrifugation. Collected lavage fluid was frozen at
80°C until Luminex analysis was performed.
Depletion of IFN-. Purified XMG1.2 (anti-IFN-) antibody was a
generous gift from Mary Ann Accavitti-Loper at the SERCEB Mouse
Monoclonal Antibody Core (University of Alabama—Birmingham).
Rat IgG1 isotype control antibody (anti-HRPN) was purchased from
BioXCell (West Lebanon, NH). Mice were administered 500 g of de-
pleting or control antibody in 200 l PBS via intraperitoneal injection on
days 0 and 2 postinoculation.
Luminex analysis. A multiplex Luminex bead-based approach was
used to quantify cytokines/chemokines in BALF or clarified tissue homog-
enate. A 20-analyte assay panel was performed according to the manufac-
turer’s protocol (Invitrogen), using a BioPlex array reader (Bio-Rad Lab-
oratories). Using integrated cytokine/chemokine standard curves, the
assay reports the following analytes in pg/ml: fibroblast growth factor
(FGF) basic, granulocyte-macrophage colony-stimulating factor (GM-
CSF), IFN-, IL-1, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70),
IL-13, IL-17, KC, monocyte chemoattractant protein 1 (MCP-1), mono-
kine induced by IFN- (MIG), macrophage inflammatory protein 1
(MIP-1), tumor necrosis factor alpha (TNF-), and vascular endothelial
growth factor. A five-parameter nonlinear logistic regression model was
used to a establish standard curve and to estimate the probability of oc-
currence of a concentration at a given point. Standard outliers were re-
moved from the analysis if the observed/expected percent recovery was
outside the acceptable limits (70 to 130%). Upper and lower levels of
quantification were determined by use of BioPlex Manager software based
on goodness of fit and percent recovery. Calculated pg/ml for experimen-
tal specimens were multiplied by the inherent assay dilution factor (df 	
2) and reported as final observed pg/ml.
Collection of spleen and lung cells. Spleens were harvested from mice
and made into a single-cell suspension. Red blood cells were lysed by using
ammonium chloride-potassium carbonate lysis buffer. Lungs were per-
fused with PBS to remove blood and then finely minced. Minced lung was
placed into 10 ml of digestion buffer containing 0.5 mg/ml collagenase I
(Worthington Biochemical), 0.02 mg/ml DNase (Sigma), and 125 U/ml
elastase (Worthington Biochemical) in RPMI 1640 (HyClone). Lungs
were digested for 30 min at 37°C and then vigorously pipetted prior to
filtering through a 100-m filter. Mononuclear cells were isolated from
the single-cell suspension by density gradient centrifugation over Lym-
pholyte M (Cedarlane Labs). Viable cells from spleen and lung were de-
termined by trypan blue exclusion using a hemacytometer.
Antibodies. The following directly conjugated antibodies were uti-
lized for flow cytometry analysis: CD3 Alexa Fluor 488 (AF488) (clone
145-2C11; eBioscience), CD4 AF700 (clone GK1.5; Biolegend), CD8a
V500 (clone 53-6.7; BD Biosciences), CD45.1 phycoerythrin (PE)-Cy7
(clone A20; Biolegend), T cell receptor (TCR) 
 peridinin chlorophyll
protein (PerCP)-Cy5.5 (clone GL3; Biolegend), IFN- PE (clone
XMG1.2; BD Biosciences), IL-17A AF647 (clone TC11-18H10.1; Bioleg-
end), CD11b Pacific Blue (clone M1/70; Biolegend), CD11c Pacific Blue
(clone N418; Biolegend), CD19 Pacific Blue (clone 6D5; Biolegend),
F4/80 Pacific Blue (clone BM8; Biolegend), GR-1 (Ly-6G) eFluor 450
(clone RB6-8C5; eBioscience), and NK1.1 Pacific Blue (clone PK136; Bio-
legend). All antibodies were titrated on normal B6 splenocytes prior to
use.
Intracellular cytokine staining. Splenocytes from B6-CD45.1 cells
were used as antigen-presenting cells. B6-CD45.1 cells were added at 2 
106 cells/well in a 24-well plate or at 0.5  106 cells/well in a 48-well plate
and infected with LVS at an MOI of 200:1 or mock infected. At 2 h postin-
fection, the medium was removed, and 5 g/ml gentamicin was added to
kill any extracellular bacteria. Splenocytes were cultured overnight in the
presence of gentamicin. Prior to coculture with cells isolated from in-
fected mice, antigen-presenting cells were washed extensively to remove
any cytokine or prostaglandin E2 (PGE2) that could interfere with the
coculture. Cells isolated from mice were cocultured at a 1:1 ratio with
infected or mock-infected splenocytes for 24 h. During the last 4 h of
culture, 10 g/ml brefeldin A (Sigma) was added to each well to stop
cytokine secretion. Cells were removed from the plate and stained with
Pacific Blue succimidyl ester (Invitrogen) to distinguish live and dead
cells. Cells were then stained with antibodies for surface markers. Follow-
ing fixation and permeabilization of the cells, cells were stained for IFN-
and IL-17A. Cells were washed extensively after each staining step to re-
move residual unbound antibody.
Gating strategy for T cell analysis. The gating scheme is shown in Fig.
S1 in the supplemental material. Single cells were discriminated from
doublets by plotting linear side scatter versus side-scatter area. Cells were
then selected by plotting side-scatter area versus forward-scatter area. Live
CD3 T cells were then selected by plotting CD3 versus the Pacific Blue
channel, which included the live/dead stain and markers for antigen-pre-
senting cells. From the CD3 gate, CD4 and CD8 T cells were selected.
Gates for IFN-- and IL-17A-positive cells were set based on isotype con-
trol staining. Delta mean fluorescent intensity (MFI) for each sample
was determined by subtracting the cytokine-negative population from the
cytokine-positive population. FlowJo v7.6 (Treestar) was used for all flow
cytometry analyses.
Determination of IFN- and IL-17A secretion by purified CD4 T
cells. B6 splenocytes were depleted of T cells by using mouse Thy1.2
Dynabeads (Life Technologies) and used as antigen-presenting cells. A
total of 5  104 T cell-depleted splenocytes/well were seeded into a 96-well
plate and then infected with LVS at an MOI of 200:1 or mock infected. At
2 h postinfection, the medium was removed, and 5 g/ml gentamicin was
added to kill any extracellular bacteria. T cell-depleted splenocytes were
cultured overnight in the presence of gentamicin. Prior to coculture with
purified CD4 T cells from infected mice, antigen-presenting cells were
washed extensively to remove any cytokine or PGE2 that could interfere
with the coculture. CD4 T cells were enriched from single-cell suspen-
sions of lung cells or splenocytes by using a Dynabeads Untouched Mouse
CD4 Cells kit (Life Technologies). Enriched CD4 T cells were cocultured
at a 1:1 ratio with T cell-depleted LVS-infected or mock-infected spleno-
cytes for 24 h. Culture supernatant was then removed and stored at 20°C
until enzyme-linked immunosorbent assay (ELISA) analysis was per-
formed. Each sample was tested in triplicate. The IFN- concentration
was determined by using a mouse IFN- Instant ELISA (eBioscience), and
the IL-17A concentration was determined by using a mouse IL-17A
Ready-Set-Go ELISA (eBioscience). T cell depletion and CD4 T cell
enrichment were determined by flow cytometry analysis. IFN- and IL-
17A concentrations were normalized based on the number of CD4 T
cells in the culture, as determined by flow cytometry.
Statistical analysis. Data were analyzed by using a one-way analysis of
variance (ANOVA) with Tukey’s posttest for cytokine levels and flow
cytometry results. Bacterial burdens were log transformed, and Student’s
t test or ANOVA with Tukey’s posttest was then applied. For LVS protec-
tion studies, a chi-square test with Yates’ correction was applied. Graph-
Pad Prism (v5.04) was used for analysis. Error bars show standard errors
of the means. Significance levels are indicated in the figures as follows: 
Barrigan et al.
2030 iai.asm.org Infection and Immunity
indicates a P value of 0.05,  indicates a P value of 0.01,  indicates
a P value of 0.001, and  indicates a P value of 0.0001.
RESULTS
LVS clpB is attenuated in mouse pneumonic tularemia. Several
groups have shown that LVS clpB or SchuS4 clpB strains are atten-
uated following either intradermal, intraperitoneal, or oral inoc-
ulation in either BALB/c or C3H/HeN mice (23–25). We were
interested in determining whether LVS clpB was also attenuated in
a pneumonic tularemia model in C57BL/6J (B6) mice. For this
study, we produced two LVS clpB mutant strains. One strain car-
ried a transposon (Tn) insertion in the clpB gene, and the other
was an in-frame deletion of the clpB coding sequence. The muta-
tions were confirmed by DNA sequencing. Although transposon
mutations can have polar effects, we did not expect any from the
transposon insertion in clpB because bioinformatic analysis indi-
cated that clpB is not located in an operon (23). Indeed, we found
that the clpB::Tn mutant and the deletion strain behaved identi-
cally in all experiments. We have therefore combined all data and
simply refer to infection with either strain as LVS clpB.
Initial experiments demonstrated that LVS clpB did not dis-
seminate when an inoculation dose of 500 CFU was used, despite
this dose causing disease following LVS inoculation. We therefore
conducted preliminary experiments to establish the dose of LVS
clpB that produced a similar peak bacteremia in the spleen so that
mice were exposed to similar antigen levels. Similar antigen loads
are important because in other infection models, the magnitude of
the primary adaptive immune response was influenced by the
peak bacterial load and not the duration of infection (29–31). As a
control for inoculation with a bacterial strain that failed to grow
intracellularly, we selected LVS dotU (32). We achieved similar
burdens for LVS and LVS clpB, but since LVS dotU fails to grow
intracellularly (32), this strain was inoculated at the highest prac-
tical dose. Seven- to twelve-week-old B6 mice were intranasally
inoculated with 5  102 CFU LVS, 5  104 CFU LVS clpB, or 5 
105 CFU LVS dotU. To determine bacterial growth in vivo, mice
were euthanized on days 3, 7, and 10 postinoculation, and bacte-
rial burdens in the spleen, liver, and lung were determined by
plating serial dilutions of tissue homogenate onto chocolate agar
(Fig. 1A to C). While LVS clpB and LVS bacterial burdens were not
significantly different in the spleen and liver at 3 days postinocu-
lation, LVS clpB bacteria were cleared much faster than LVS from
all organs tested. Few LVS clpB colonies were recovered at 10 days
postinoculation, while LVS-infected mice still had high bacterial
loads, particularly in the lung. Despite the 1,000-fold-higher dose
of LVS dotU than of LVS, the number of colonies recovered from
the lungs at 3 days postinoculation was 1,000-fold lower than the
number of LVS colonies. Viable LVS dotU organisms were recov-
ered from isolated lung cells from LVS dotU-infected mice har-
vested at 3 days postinoculation and cultured in gentamicin for 1
h, demonstrating that LVS dotU was internalized and that the
bacteria had not simply persisted in the extracellular space (see
Fig. S2 in the supplemental material). Despite its intracellular lo-
cation, LVS dotU failed to leave the lung and transit to the spleen
and liver and was effectively cleared by 7 days postinoculation in
all organs tested. Because LVS dotU was not found in distal organs
on day 3 postinoculation, but infected cells were still present in the
lung, these data suggest that infected cells were not the primary
method of dissemination. Alternatively, the LVS dotU-infected
cells were not activated in a manner that caused them to leave the
primary site of infection. To confirm that rapid clearance of LVS
FIG 1 LVS clpB-infected mice clear bacteria faster and exhibit less disease. B6 mice were intranasally inoculated with LVS (5  102 CFU), LVS clpB (5  104
CFU), or LVS dotU (5  105 CFU). (A to C) On days 3, 7, and 10 postinoculation, bacterial burdens in the lung (A), liver (B), and spleen (C) were determined
by plating serial dilutions of organ homogenate onto chocolate agar (n 	 5 to 12 mice/group). Data are combined from at least 4 independent experiments per
time point. The dashed line indicates the limit of detection of 50 CFU. Statistical significance was determined on log-transformed data by using ANOVA with
Tukey’s posttest (days 3 and 7) or Student’s t test (day 10). (D) Mouse weight was determined daily and is reported as a percentage of the starting weight (n 	 25
to 32 mice/group).
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clpB and LVS dotU was due specifically to the absence of these
genes, the strains were trans-complemented. B6 mice were intra-
nasally inoculated with 5  102 CFU of LVS clpB complement or
LVS dotU complement. We used the same dose as LVS since
transcomplementation should return these strains to wild-type
LVS virulence levels. Indeed, transcomplementation of LVS clpB
and LVS dotU led to bacterial burdens comparable to those of LVS
in the spleen, liver, and lungs at 3 days postinoculation (see Fig. S3
in the supplemental material). Overall, these results demonstrate
that LVS clpB is attenuated in a pneumonic model of tularemia,
just as other groups have shown for LVS clpB and SchuS4 clpB by
different routes of inoculation (23–25).
We also wanted to understand if the extent of disease caused by
LVS clpB was similar to that caused by LVS. As a measure of overall
health, body weight change is a reasonable measure of clinical status.
Infected mice were weighed daily, and weight loss as a percentage of
the starting weight was reported (Fig. 1D). LVS-infected mice lost
nearly 15% of their starting weight by day 7 and then slowly regained
weight. In contrast to LVS, LVS clpB-infected mice only lost approx-
imately 10% of their starting weight and began to regain weight at 5
days postinoculation. LVS clpB-infected mice regained their lost
weight more rapidly than did LVS-infected mice, which correlated
with faster bacterial clearance. Mice infected with LVS dotU did not
lose any weight, an expected result given that the bacteria failed to
grow in vivo. Together, these results indicate that LVS clpB is attenu-
ated in pneumonic tularemia and leads to a weight loss profile that
differed from that of LVS infection.
Previous infection with LVS clpB protects against lethal LVS
intranasal challenge. We next sought to determine whether pre-
vious intranasal inoculation with LVS, LVS clpB, or LVS dotU
elicits an immune response that was protective against a subse-
quent lethal LVS intranasal challenge. Mice were intranasally in-
oculated with 5  102 CFU LVS, 5  104 CFU LVS clpB, or 5  105
CFU LVS dotU. To examine the early memory response, mice
were challenged with 5  103 CFU (approximately 5 LD50 [8]) of
LVS intranasally 28 days after the initial infection. All mice vacci-
nated with LVS or LVS clpB survived lethal LVS challenge
(Fig. 2A). LVS- and LVS clpB-vaccinated mice lost little weight
following lethal LVS challenge and quickly returned to their start-
ing weight (Fig. 2B). Naïve and LVS dotU-vaccinated mice con-
tinued to lose weight after LVS- and LVS clpB-vaccinated mice
began their recovery. The abrupt change in the weight loss curve
for the LVS dotU-vaccinated group is due to the one surviving
mouse. Naïve mice fell below the weight loss threshold at 6 or 7
days after rechallenge. Five of six LVS dotU-vaccinated mice suc-
cumbed to infection 6 days after the lethal dose challenge. There
was no significant difference in survival when LVS dotU-vacci-
nated mice were compared to the naïve group. The surviving LVS
dotU-vaccinated mouse lost more than 20% of its starting weight
but never fell below the 25% threshold after challenge with LVS.
Despite sustained illness, indicated by weight loss in this mouse,
there were no colonies recovered from the spleen, liver, or lung 14
days following the lethal challenge, similar to mice following pri-
mary exposure to LVS.
FIG 2 LVS clpB protects against a lethal secondary LVS challenge 28 or 120 days after primary infection. B6 mice were intranasally inoculated with LVS (5  102
CFU), LVS clpB (5  104 CFU), or LVS dotU (5  105 CFU) or left uninfected. (A) Twenty-eight days after primary infection, mice were challenged intranasally
with 5  103 CFU LVS, and survival was measured (n 	 6 to 12 mice/group). Data are combined from 2 independent experiments. A chi-square test with Yates’
correction was used to compare survival of the vaccinated groups to that of the naïve group (naïve versus LVS, P  0.001; naïve versus LVS clpB, P  0.0001; naïve
versus LVS dotU, not significant). (B) Mice were weighed daily following secondary infection with LVS, and weight loss is reported as a percentage of the starting
weight. Weight loss by the surviving LVS dotU-vaccinated mouse is reported (n 	 6 to 12 mice/group). Data are combined from 2 independent experiments. (C)
Bacterial burdens in the lung on day 6 after rechallenge (n 	 5 to 7 mice/group). Data are compiled from 2 independent experiments. The dashed line indicates
the limit of detection of 50 CFU. Statistical significance was determined on log-transformed data by using ANOVA with Tukey’s posttest. (D) One hundred
twenty days after primary infection, mice were challenged with 5  103 CFU LVS, and survival was measured (n 	 12 to 15 mice/group). Data are combined from
2 independent experiments. A chi-square test with Yates’ correction was used to compare survival of the vaccinated groups to the naïve group (naïve versus LVS,
P  0.001; naïve versus LVS clpB, P  0.0001; naïve versus LVS dotU, not significant). (E) Mice were weighed daily following secondary infection with LVS, and
weight loss is reported as a percentage of the starting weight. Weight loss by the surviving LVS dotU-vaccinated mouse is reported (n 	 12 to 15 mice/group). Data
are combined from 2 independent experiments. (F) Bacterial burdens in the lung on day 6 after rechallenge (n 	 6 to 8 mice/group). Data are combined from
2 independent experiments. The dashed line indicates the limit of detection of 50 CFU. Statistical significance was determined on log-transformed data by using
ANOVA with Tukey’s posttest.
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When naïve and LVS dotU-vaccinated mice were sacrificed
upon losing 25% of their starting weight (day 6 after rechal-
lenge), we harvested spleen, liver, and lung and determined bac-
terial burdens (Fig. 2C). We also harvested spleen, liver, and lung
from LVS- and LVS clpB-vaccinated mice on day 6 postinfection
and determined bacterial burdens for comparison purposes
(Fig. 2C). Naïve and LVS dotU-vaccinated mice had high bacterial
burdens in the lung, with means exceeding 107 CFU. High bacte-
rial burdens were also observed for the spleens and livers of naïve
and LVS dotU-vaccinated mice compared to the few or no colo-
nies recovered from LVS- or LVS clpB-vaccinated mice (data not
shown). No colonies were recovered from the lungs of LVS-vac-
cinated mice and 4 of 6 LVS clpB-vaccinated mice.
We were also interested in whether LVS clpB would confer
long-lived protection against lethal LVS challenge. Mice were in-
tranasally inoculated with 5  102 CFU LVS, 5  104 CFU LVS
clpB, or 5  105 CFU LVS dotU and then challenged with 5  103
CFU LVS intranasally 120 days after the initial infection. All LVS-
and LVS clpB-vaccinated mice survived lethal LVS challenge (Fig.
2D). All naïve mice succumbed to their infection by day 7. Over
half of the LVS dotU-vaccinated mice succumbed to their infec-
tion by day 7, and all but one mouse succumbed by day 14. The
surviving LVS dotU-vaccinated mouse lost more than 20% of its
starting weight but never fell below the 25% threshold for sacri-
fice. This mouse was sacrificed on day 14, and the bacterial bur-
dens in the spleen, liver, and lung were determined. A total of 125
CFU were recovered from the spleen, 0 CFU were recovered for
the liver, and 425 CFU were recovered from the lung, indicating
that this mouse was clearing the high-dose LVS challenge. When
mice were challenged 120 days after vaccination, the LVS- and
LVS clpB-vaccinated groups lost more weight (approximately 10
to 15% of their starting weight) than the same groups challenged
28 days after vaccination (Fig. 2E). LVS- and LVS clpB-vaccinated
mice not only showed equivalent weight loss after high-dose LVS
challenge but also regained their lost weight at a similar pace.
Naïve and LVS dotU-vaccinated mice also showed similar weight
loss profiles compared to each other. Figure 2E also shows that the
surviving LVS dotU-vaccinated mouse exhibited extreme weight
loss but rapidly gained weight on days 13 and 14.
When naïve and LVS dotU-vaccinated mice fell below the
weight loss threshold on day 6, four mice per group were sacri-
ficed, and bacterial burdens in the spleen, liver, and lung were
determined (Fig. 2F). Only the number of CFU in the lung is
shown; however, a similar trend was seen for the spleen and liver
(data not shown). Naïve and LVS dotU-vaccinated mice had high
bacterial burdens that were comparable to the burdens found
when mice were challenged 28 days after vaccination. LVS- and
LVS clpB-vaccinated mice had approximately 104 CFU in their
lungs on day 6 after the high-dose LVS challenge. These results
clearly indicate that LVS clpB protects against subsequent lethal
LVS challenge.
Since LVS clpB induced a robust adaptive immune response
that protected against a lethal LVS challenge, we next wanted to
determine whether LVS clpB could protect against aerosolized,
highly virulent SchuS4. Mice were intranasally inoculated with
5  102 CFU LVS, 5  104 CFU LVS clpB, or 5  105 CFU LVS
dotU and then challenged with 30 CFU SchuS4 (measured as the
dose retained in the lungs at 1 h, approximately 30 LD100 [8]) via
the aerosol route 28 days after the initial infection. The use of
aerosolized SchuS4 in B6 mice is a very stringent test of whether
LVS clpB infection confers protection. Previous vaccination with
LVS protected 2 of 7 mice, and LVS clpB vaccination protected 1 of
8. These results are consistent with the findings of others who have
also shown that previous LVS infection does not fully protect
against SchuS4 challenge in B6 mice (33, 34). Naïve and LVS
dotU-vaccinated mice succumbed to SchuS4 infection at 5 days
postinfection. While neither LVS nor LVS clpB vaccination pro-
vided complete protection against subsequent SchuS4 infection,
these infections significantly increased the median survival time
from 5 days (naïve) to 9 days (LVS clpB) or 10 days (LVS) (see Fig.
S4 in the supplemental material). A Mantel-Cox log-rank test was
used to compare the survival of the vaccinated groups to the sur-
vival of the naïve group. Survival with LVS dotU vaccination was
not statistically different from that of the naïve group, but LVS and
LVS clpB vaccination significantly increased survival after SchuS4
challenge (P  0.001).
LVS clpB does not exhibit an intracellular growth defect. A
bacterial strain’s attenuation could be the result of a growth defect
or an altered immune response that is more effective at bacterial
clearance. We therefore sought to determine whether our LVS
clpB or LVS dotU strain had a growth defect in broth or intracel-
lularly that could explain its attenuation in vivo. We initially ex-
amined the ability of LVS, LVS clpB, and LVS dotU to grow in
either CDM (minimal) or BHI broth (rich). We inoculated cul-
tures with log-phase bacteria and monitored the OD600 every 15
min for 48 h. The growth rates of the three strains in CDM and
BHI broth were nearly identical (Fig. 3A and B). Therefore, there
is no inherent growth difference in vitro.
We next determined whether LVS clpB or LVS dotU had an
intracellular growth defect in primary BMDMs or the cell lines
A549 (human alveolar type II epithelial), J774 (mouse macro-
phage), and MH-S (mouse alveolar macrophage). Cells were in-
oculated with LVS or LVS clpB at an MOI of 25:1 for 120 min to
allow internalization. Cells were then treated with gentamicin to
kill extracellular bacteria. To determine bacterial internalization,
macrophages were lysed 4 h after inoculation, and serial dilutions
of the lysate were plated onto chocolate agar. We recovered similar
numbers of both LVS and LVS clpB CFU within each different cell
type at 4 h postinoculation, indicating that LVS clpB is not defec-
tive for internalization (Fig. 3C to F). To determine the ability of
LVS clpB to grow in BMDMs, we lysed infected cells at 24 h post-
inoculation and plated serial dilutions of the lysate onto chocolate
agar. We found a similar increase in the number of CFU recovered
for LVS and LVS clpB within each cell line, indicating that LVS
clpB has no intracellular growth defect (Fig. 3C to F). Because LVS
clpB grows in a variety of cell lines, these data indicate that the
ability of LVS clpB to grow intracellularly is generalizable and not
specific to a certain cell type. Although LVS dotU infected all cells
tested so that it was protected from gentamicin similarly to LVS at
4 h postinoculation, this strain failed to grow, and a similar num-
ber of or even fewer CFU were recovered at 24 h postinoculation
(Fig. 3C to F). We could rescue the intracellular growth defect seen
with LVS dotU by trans-complementation (see Fig. S5 in the sup-
plemental material). These results indicate that the in vivo atten-
uation of LVS dotU is likely a consequence of this strain’s inability
to grow intracellularly. Indeed, LVS dotU and U112 dotU failed to
escape the phagosome (32, 35) to reach the cytosol, the replicative
niche of Francisella. However, since LVS clpB has no intracellular
growth defect, its attenuation may be caused by an altered im-
mune response that is more effective at bacterial clearance.
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LVS clpB fails to inhibit early proinflammatory cytokine pro-
duction in the lung. Because LVS clpB did not exhibit an intracel-
lular growth defect, we hypothesized that this strain’s attenuation
was due to an altered immune response that was more effective at
bacterial clearance. To test our hypothesis, we first examined cy-
tokine production in the lung BALF on day 3 postinoculation
using a 20-plex mouse cytokine Luminex assay. Despite higher
lung bacterial burdens in LVS-infected B6 mice on day 3 postin-
oculation than in LVS clpB-infected B6 mice (Fig. 1A), the BALF
of LVS-infected B6 mice contained fewer proinflammatory cyto-
kines and chemokines than the BALF of LVS clpB-infected B6
mice (Fig. 4). LVS clpB also induced a similar profile of proinflam-
FIG 3 LVS clpB does not exhibit an intracellular growth defect. (A and B) LVS, LVS clpB, and LVS dotU growth in CDM (A) or BHI broth (B) was determined
by using a Tecan Infinite M200 plate reader by measuring the OD600 every 15 min for 48 h. Data shown are the averages of data from triplicate wells and are
representative of at least 3 independent experiments per strain. (C to F) B6 bone marrow-derived macrophages (BMDMs) (C) or A549 (D), J774 (E), or MH-S
(F) cells were infected with LVS, LVS clpB, or LVS dotU at an MOI of 25:1. Cells were lysed at either 4 or 24 h postinoculation, and serial dilutions of the lysate
were plated onto chocolate agar to determine the number of bacteria present. Cells were infected with each strain in triplicate, and lysates from each sample were
plated in duplicate. Data are representative of at least 2 independent experiments.
FIG 4 LVS clpB induces a proinflammatory response in the lung early after infection. B6 or BALB/c mice were intranasally inoculated with LVS (5  102 CFU)
or LVS clpB (5  104 CFU) or left uninfected. At 3 days postinoculation, BALF was collected, and cytokine and chemokine concentrations were determined by
using a Luminex-based assay. Cytokine and chemokines levels were first normalized to the levels in uninfected mice, and the fold increase in cytokine or
chemokine concentrations from LVS clpB-infected mice over LVS-infected mice was then determined for each infected group; values are indicated in boldface
type if they exceeded 2-fold (n 	 4 to 7 mice/group). Data are combined from at least 2 independent experiments per mouse strain. ANOVA with Tukey’s posttest
was used to determine significant changes in cytokine and chemokine concentrations within each mouse strain. LVS clpB levels were significantly higher (P 
0.05) than LVS levels in both mouse strains for IP-10, KC, IL-12, and TNF-. LVS clpB levels were significantly higher (P  0.05) than LVS levels in B6 mice for
IFN-, IL-6, and GM-CSF. LVS clpB levels were significantly higher (P  0.05) than LVS levels in BALB/c mice for MIG.
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matory cytokines and chemokines in the lungs of BALB/c mice on
day 3 postinoculation, whereas LVS did not (Fig. 4). BALB/c mice
also had significantly higher day 3 postinoculation lung LVS bur-
dens than LVS clpB (see Fig. S6 in the supplemental material).
Clearly, LVS clpB failed to suppress early proinflammatory cyto-
kine production in the lung, which is in stark contrast to LVS
infection, which does not induce proinflammatory cytokine pro-
duction in the lung (Fig. 4) (11). Additionally, the failure of LVS
clpB to suppress proinflammatory cytokine production is not spe-
cific to a particular mouse strain, as the same effect was seen in B6
and BALB/c mice. Despite the high-inoculum dose of LVS dotU,
this strain did not elicit any detectable proinflammatory cytokine
production in the lungs of infected B6 or BALB/c mice (data not
shown).
Depletion of IFN- early after LVS clpB inoculation in-
creases bacterial burdens. To confirm that proinflammatory cy-
tokine production early after inoculation was important for in-
nate immunity-mediated bacterial clearance, we treated B6 mice
with 500 g of XMG1.2 (anti-IFN-) or rat IgG1 isotype antibody
on day 0 and day 2 postinoculation. On day 3 postinoculation,
mice were sacrificed, and bacterial burdens in the spleen, liver, and
lung were determined. Mice receiving IFN--depleting antibody
had significantly higher bacterial burdens in all organs than mice
receiving isotype control antibody (see Fig. S7A to S7C in the
supplemental material). We confirmed IFN- depletion by sub-
jecting clarified tissue homogenates to Luminex analysis. All mice
receiving anti-IFN- depleting antibody had IFN- levels below
the detection limit, whereas isotype control animals had high lev-
els of lung IFN- (see Fig. S7D in the supplemental material).
These data indicate that proinflammatory cytokine production,
such as IFN-, early after LVS clpB inoculation helps control bac-
terial replication.
Adaptive immunity is required for LVS clpB clearance. LVS
clearance requires adaptive immunity (15). Because LVS clpB in-
duced a robust innate immune response and was nearly cleared
from the host prior to the peak of the adaptive immune response
(day 10 postinoculation [19]), this raised the possibility that the
innate immune system was capable of controlling the infection
and mediating bacterial clearance without the requirement of
adaptive immunity, even though the adaptive response was vigor-
ous (see below). To test this possibility, we infected B6 and Rag/
mice with 5  104 CFU LVS clpB. On days 3 and 7 postinfection,
B6 and Rag/ mice had equivalent bacterial burdens in the lung,
indicating that innate immunity was capable of controlling the
infection initially (Fig. 5A). We next infected Rag/ and B6 mice
with 5  104 CFU LVS clpB and harvested organs at 28 days post-
inoculation. No bacteria were recovered from the B6 mice, but
LVS clpB persisted in the lungs of Rag/ mice (Fig. 5A). The same
trend was seen for the spleen and liver (data not shown). Despite
persistent bacteremia with LVS clpB in Rag/ mice, weight loss
profiles were identical for Rag/ and B6 mice (Fig. 5B). Since
LVS clpB persisted in Rag/ mice, this result indicates that adap-
tive immunity is required for LVS clpB clearance, similar to LVS
(15); the robust innate response is not sufficient to clear LVS clpB.
This further suggests that the innate immune response is respon-
sible for the weight loss profile observed for LVS clpB-inoculated
mice.
LVS clpB infection induces altered immune expansion. After
determining that adaptive immunity is required for LVS clpB
clearance, we characterized the adaptive immune response to this
strain. First, we determined the total number of cells recovered
from the spleen and lung on days 7 and 10 postinoculation
(Fig. 6). LVS- and LVS clpB-infected mice had similar increases in
spleen cellularity, with an approximately 2- to 3-fold increase in
the total number of cells compared to uninfected mice on days 7
and 10 postinoculation (Fig. 6A and B). LVS- and LVS clpB-in-
fected mice also had increased lung cellularity of 2- to 5-fold over
that of uninfected mice on days 7 and 10 postinoculation (Fig. 6C
and D). When spleen cellularity of LVS- and LVS clpB-infected
mice was compared, there was no significant difference on day 7 or
10 postinoculation (Fig. 6A and B). However, lung cellularity was
decreased significantly in LVS clpB-infected mice compared to
LVS-infected mice on days 7 and 10 postinoculation (Fig. 6C and
D). The difference in lung cellularity is likely due to the contrac-
tion of the immune response following LVS clpB clearance. While
the LVS clpB infection was nearly cleared on day 10 postinocula-
tion, LVS-infected mice still had high bacterial burdens, and an
ongoing infection likely drives sustained lung cellularity. Because
LVS dotU failed to grow in vivo, it was not surprising that LVS
dotU-infected mice did not have any increase in spleen or lung
cellularity compared to uninfected mice and exhibited no im-
mune expansion from days 7 to 10 (Fig. 6A to D).
LVS clpB infection induced a robust IFN--mediated im-
mune response similar in magnitude to that induced by LVS
infection. Given the strong innate response, we suspected that in
spite of the earlier clearance of LVS clpB, we would still observe a
robust adaptive response. We therefore examined whether IFN-
production by CD4 T cells was altered after LVS clpB infection
(Fig. 7A to D). We identified IFN--producing T cells using intra-
FIG 5 Adaptive immunity is required for LVS clpB clearance. B6 or Rag/
mice were intranasally inoculated with 5  104 CFU LVS clpB. (A) Bacterial
burdens were determined in the lung on days 3, 7, 10, and 28 postinoculation
by plating serial dilutions of organ homogenate onto chocolate agar (n 	 6 to
8 mice/group). Data are combined from 2 independent experiments. The
dashed line indicates the limit of detection of 50 CFU. Statistical significance
was determined on log-transformed data by using Student’s t test. (B) Mouse
weight was determined daily and is reported as a percentage of the starting
weight (n 	 6 to 8 mice/group). Data are combined from 2 independent
experiments.
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cellular cytokine staining following coculture with LVS-infected
congenic B6-CD45.1 splenocytes as antigen-presenting cells. The
gating scheme used for all flow cytometry analyses is shown in Fig.
S1 in the supplemental material. We found no statistically signif-
icant difference in the number of CD4 T cells producing IFN-
in the spleen and lung in LVS- and LVS clpB-infected mice on day
7 (Fig. 7A and B). On day 10 postinoculation, the number of
splenic CD4 IFN- T cells was not significantly different be-
tween LVS- and LVS clpB-infected mice in spite of lower bacterial
burdens in LVS clpB-infected mice (Fig. 7C). In the lung, however,
there was a significant decrease in the number of CD4 IFN- T
cells in LVS clpB-infected mice compared to LVS-infected mice
(Fig. 7D). While the frequency of IFN- cells in the CD4 T cell
pool in LVS clpB-infected mice was higher than that in LVS-in-
fected mice (41.6% versus 35.8%), the difference did not reach
statistical significance. Because the frequency of IFN- cells of
CD4 T cells was similar in the lungs of LVS- and LVS clpB-
infected mice, the difference in the absolute number was due to
fewer total cells in the lungs of LVS clpB-infected mice on day 10
postinoculation (Fig. 6D). We did not detect an increase in the
number of splenic or lung CD4 IFN- cells in LVS dotU-in-
fected mice compared to uninfected mice (Fig. 7A to D).
CD8 T cells showed a pattern of IFN- production similar to
that of CD4 T cells (Fig. 7E to H). There was no statistical differ-
ence in the number of CD8 IFN- T cells in the spleen or lungs
of LVS- and LVS clpB-infected mice on day 7 postinoculation (Fig.
7E and F). On day 10 postinoculation, there were equivalent num-
bers of CD8 T cells producing IFN- in the spleens of LVS clpB-
and LVS-infected mice (Fig. 7G). There was, however, a signifi-
cant decrease in the number of IFN- CD8 T cells in the lungs
of LVS clpB-infected mice on day 10 postinoculation compared to
LVS-infected mice (Fig. 7H). Again, the percentages of IFN-
FIG 6 LVS and LVS clpB infection leads to increased spleen and lung cellu-
larity. B6 mice were intranasally inoculated with LVS (5  102 CFU), LVS clpB
(5  104 CFU), or LVS dotU (5  105 CFU) or left uninfected. The total
number of cells in the spleen or lung was determined on days 7 and 10 post-
inoculation by trypan blue exclusion (n 	 4 to 9 mice/group). Data are com-
bined from at least 4 independent experiments. Statistical significance was
determined by using an ANOVA with Tukey’s posttest. (A) Total number of
cells in the spleen on day 7 postinoculation. (B) Total number of cells in the
spleen on day 10 postinoculation. (C) Total number of cells in the lung on day
7 postinoculation. (D) Total number of cells in the lung on day 10 postinocu-
lation.
FIG 7 LVS and LVS clpB infection leads to increased IFN- CD4 and CD8 T cells. B6 mice were intranasally inoculated with LVS (5  102 CFU), LVS clpB
(5  104 CFU), or LVS dotU (5  105 CFU) or left uninfected. On days 7 and 10 postinoculation, splenocytes or isolated lung cells were restimulated with
LVS-infected B6-CD45.1 antigen-presenting cells for 24 h. Brefeldin A was added during the last 4 h of coculture (n 	 4 to 9 mice/group). Data are combined
from at least 4 independent experiments. Statistical significance was determined by using an ANOVA with Tukey’s posttest. (A) Number of IFN--producing
CD4 cells in the spleen at 7 days postinoculation. (B) Number of IFN--producing CD4 cells in the lung at 7 days postinoculation. (C) Number of
IFN--producing CD4 cells in the spleen on day 10 postinoculation. (D) Number of IFN--producing CD4 cells in the lung on day 10 postinoculation. (E)
Number of IFN--producing CD8 cells in the spleen at 7 days postinoculation. (F) Number of IFN--producing CD8 cells in the lung at 7 days postinocu-
lation. (G) Number of IFN--producing CD8 cells in the spleen on day 10 postinoculation. (H) Number of IFN--producing CD8 cells in the lung on day 10
postinoculation.
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cells in the CD8 T cell pool remained the same; therefore, any
decrease in absolute number on day 10 is due to decreased lung
cellularity in LVS clpB-infected mice. Uninfected and LVS dotU-
infected mice were similar to each other in terms of the absolute
number of CD8 IFN- cells in the spleen and lungs on days 7
and 10 postinoculation (Fig. 7E to H).
We found an approximately 2-fold increase in the number of
IFN- CD4 T cells in the spleens of LVS- and LVS clpB-infected
mice between days 7 and 10 postinoculation (Fig. 7A and C).
There was at least a 10-fold expansion of IFN- CD4 T cells in
the lungs of LVS- and LVS clpB-infected mice between days 7 and
10 postinoculation (Fig. 7B and D). LVS clpB-infected mice, how-
ever, did not show the degree of expansion seen in LVS-infected
mice (10-fold versus 35-fold). There was no change in the number
of IFN- CD8 T cells in the spleens of LVS- or LVS clpB-in-
fected mice between days 7 and 10 postinoculation (Fig. 7E and
G). There was, however, an approximately 10-fold increase in the
number of responding IFN- CD8 T cells in the lungs of both
LVS- and LVS clpB-infected mice between days 7 and 10 (Fig. 7F
and H). Together, these results indicate that LVS clpB infection
induced a frequency of IFN- CD4 and CD8 T cells similar to
that induced by LVS infection.
LVS clpB infection led to increased IFN- expression by re-
sponding T cells compared to LVS infection. We next measured
the mean fluorescence intensity (MFI) of CD4 IFN- cells be-
cause MFI is an indication of how much IFN- is expressed on a
per-cell basis. We normalized the data by subtracting the MFI of
the IFN--negative population from the MFI of the IFN--posi-
tive population to give a change in MFI (MFI). Figure 8A to D
shows data for CD4 IFN- MFI combined from 4 indepen-
dent experiments. The differences in MFI for CD4 IFN- T
cells on day 10 were consistent from experiment to experiment,
and representative histograms derived from the same experiment
are shown (Fig. 8E to H). There was a significant increase in the
MFI of CD4 cells producing IFN- in the spleens and lungs
from LVS- and LVS clpB-infected mice compared to uninfected
mice on day 7 and 10 postinoculation (Fig. 8A to D). On day 7
postinoculation, there was no significant difference in CD4
IFN- MFI from LVS-infected mice compared to LVS clpB-in-
fected mice in both the spleen and lung (Fig. 8A and B). However,
on day 10, there was a significant increase in IFN- MFI from
LVS clpB-infected mice compared to LVS-infected mice in both
the spleen and lung (Fig. 8C and D). To further investigate IFN-
production by CD4 T cells, we enriched CD4 T cells from the
spleen and lung on day 10 postinoculation. We chose day 10 be-
cause this time point had more responding CD4 T cells than at
day 7 and also exhibited differences in IFN- expression, as mea-
sured by MFI. Enriched lung and spleen CD4 T cells were re-
stimulated by using LVS-infected T cell-depleted splenocytes. The
concentration of IFN- in the culture supernatant was deter-
mined by ELISA 24 h after the start of the coculture and was
normalized to the number of CD4 T cells in each sample (see Fig.
S8 in the supplemental material). There was no difference in the
IFN- concentration following restimulation of enriched lung or
spleen CD4 T cells from LVS- or LVS clpB-infected mice. It is
possible that we did not see the difference in IFN- production by
CD4 T cells because of IFN- turnover during the culture. Ad-
ditionally, intracellular cytokine staining is a much more sensitive
technique than ELISA of culture supernatants.
The IFN- MFI trend for CD8 T cells is similar to that for
the CD4 T cell subset. Representative histograms derived from
the same experiment for IFN- CD8 T cells from LVS- and LVS
clpB-infected mice are shown (Fig. 8M to P). Measurement of
IFN- MFI in the spleen and lung showed similar expression
levels of IFN- at 7 days postinoculation in LVS- and LVS clpB-
infected mice (Fig. 8I and J). There was a significant increase in the
MFI of IFN- cells in the CD8 T cell pool in the spleen and
lung in LVS clpB-infected mice compared to LVS-infected mice on
day 10 postinoculation (Fig. 8K and L). The IFN- MFI in CD8
T cells indicates that like CD4 T cells, the cells from LVS clpB-
infected mice express more IFN- than do cells isolated from LVS-
infected mice, even though fewer cells are present.
LVS clpB infection increases IL-17 expression levels com-
pared to LVS infection. Th17 cells are also involved in the im-
mune response during pneumonic tularemia (19, 20). Although
there was no significant change at day 7 postinoculation, by day 10
postinoculation, there was a significant increase in the absolute
number of CD4 IL-17A T cells in the lungs of LVS-infected
mice compared to uninfected mice (Fig. 9C and D). LVS clpB-
infected mice trended toward more CD4 IL-17A T cells in the
lungs on day 10 postinoculation than in uninfected mice, but the
difference did not reach statistical significance (Fig. 9D). There
was no significant difference in the absolute number of Th17 cells
in the lungs of LVS- and LVS clpB-infected mice on day 10 post-
inoculation (Fig. 9D). There was also an expansion of Th17 cells in
the lung between days 7 and 10 postinoculation for LVS- and LVS
clpB-infected mice, with nearly a 10-fold increase in cell number
(Fig. 9C and D). Interestingly, there was a significant increase of
IL-17A MFI in the lung of LVS clpB-infected mice on day 10
postinoculation compared to LVS-infected mice (Fig. 9H). The
absolute number of splenic CD4 T cells producing IL-17A was
similar on days 7 and 10 postinoculation among uninfected and
LVS-, LVS clpB-, and LVS dotU-infected mice, indicating that
Th17 cells are not responding to infection in the spleen (Fig. 9A
and B). There was also no significant difference in the splenic
IL-17A MFI when all groups of mice were compared (Fig. 9E and
F). We also determined IL-17 secretion by enriched CD4 T cells
from the lung and spleen on day 10. These cells were restimulated
with LVS-infected, T cell-depleted splenocytes, and the concen-
tration of IL-17 was determined by ELISA (see Fig. S9 in the sup-
plemental material). Enriched CD4 T cells from the lungs of
LVS- and LVS clpB-infected mice secreted similar amounts of IL-
17. Overall, our results suggest that Th17 expansion occurs largely
at the site of primary infection.
Altogether, our results demonstrate that LVS clpB infection
induces altered host immunity compared to wild-type LVS infec-
tion. First, we saw early proinflammatory cytokine production in
the lungs of LVS clpB-infected mice, a process that was inhibited
during LVS infection. Additionally, LVS clpB-infected mice pro-
duced an expansion of Th1, Th17, and CD8 T cell responses at
least equivalent to that of LVS-infected mice, with lower bacterial
burdens and a shorter duration of infection.
DISCUSSION
Bacterial attenuation can be the consequence of a strain’s failure to
grow, as in the case of auxotrophs, or a strain’s failure to inhibit
components of host immunity. Both in vitro and in vivo screens
have identified Francisella virulence determinants, and several of
those screens identified clpB as a gene required for virulence (5–7,
36). While several groups described a slight intracellular growth
F. tularensis clpB Induces an Altered Immune Response
June 2013 Volume 81 Number 6 iai.asm.org 2037
FIG 8 CD4 and CD8 T cells from LVS clpB-infected mice express more IFN- per cell than do those from LVS-infected mice. B6 mice were intranasally
inoculated with LVS (5  102 CFU), LVS clpB (5  104 CFU), or LVS dotU (5  105 CFU) or left uninfected. On days 7 and 10 postinfection, splenocytes or
isolated lung cells were restimulated with LVS-infected B6-CD45.1 antigen-presenting cells for 24 h. Brefeldin A was added during the last 4 h of coculture. To
determine the relative mean fluorescent intensity (MFI) for each sample, the MFI of the IFN--negative population was subtracted from the MFI of the
IFN--positive population (n 	 4 to 9 mice/group). Data are combined from at least 4 independent experiments. Statistical significance was determined by using
an ANOVA with Tukey’s posttest. (A) IFN- MFI for CD4 T cells in the spleen at 7 days postinoculation. (B) IFN- MFI for CD4 T cells in the lung at 7
days postinoculation. (C) IFN- MFI for CD4 T cells in the spleen at 10 days postinoculation. (D) IFN- MFI for CD4 T cells in the lung at 10 days
postinoculation. (E) Representative histograms of the IFN- CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the spleen on day
7 postinoculation. (F) Representative histograms of the IFN- CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the lung on day 7
postinoculation. (G) Representative histograms of the IFN- CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the spleen on day
10 postinoculation. (H) Representative histograms of the IFN- CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the lung
on day 10 postinoculation. (I) IFN- MFI for CD8 T cells in the spleen at 7 days postinoculation. (J) IFN- MFI for CD4 T cells in the lung at 7 days
postinoculation. (K) IFN- MFI for CD8 T cells in the spleen at 10 days postinoculation. (L) IFN- MFI for CD8 T cells in the lung at 10 days
postinoculation. (M) Representative histograms of the IFN- CD8 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the spleen
on day 7 postinoculation. (N) Representative histograms of the IFN- CD8 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in
the lung on day 7 postinoculation. (O) Representative histograms of the IFN- CD8 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected
mice in the spleen on day 10 postinoculation. (P) Representative histograms of the IFN- CD8 T cells from LVS (solid line)- and LVS clpB (dotted
line)-infected mice in the lung on day 10 postinoculation.
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defect for clpB strains (23, 37, 38), we did not see an intracellular
growth defect for our LVS clpB strains in the cell types that we
tested. This result suggested that something else was responsible
for the attenuation of clpB in animal models of infection (23–25).
We therefore hypothesized that LVS clpB induces an altered im-
mune response that mediates faster bacterial clearance.
To test our hypothesis, we first confirmed that our LVS clpB
strain was attenuated in a pneumonic model of tularemia. In order
to achieve similar bacterial burdens early after infection, we inoc-
ulated mice with a 100-fold-higher dose of LVS clpB than of LVS.
Ideally, we would have used the same inoculation dose for both
bacterial strains. However, not only did LVS clpB fail to dissemi-
nate to the spleen and liver in all mice, the bacterial burdens were
also significantly lower in all organs tested on day 3 postinocula-
tion at an inoculation dose of 5  102 CFU. An inoculation dose of
5  104 CFU of LVS clpB led to bacterial burdens similar to those
of LVS at 3 days postinoculation and allowed us to examine dif-
ferences in the adaptive immune response in the absence of large
differences in the overall antigen load. Despite similar bacterial
burdens early after inoculation, we observed rapid clearance of
LVS clpB. Even though LVS clpB was cleared rapidly from the host,
this strain did elicit an adaptive immune response that developed
into protective memory. Importantly, previous infection with
LVS clpB provided protection equivalent to that provided by LVS
against subsequent lethal LVS intranasal inoculation. The bacte-
rial burdens in LVS- and LVS clpB-vaccinated mice infected 120
days after vaccination were higher than those in the same groups
challenged 28 days after vaccination. The increase in bacterial bur-
den was consistent with the increased weight loss seen when mice
were challenged 120 days after vaccination. Because the number of
FIG 9 Th17 cells from LVS clpB-infected mice express more IL-17 than do cells from LVS-infected mice. B6 mice were intranasally inoculated with LVS (5  102
CFU), LVS clpB (5  104 CFU), or LVS dotU (5  105 CFU) or left uninfected. On days 7 and 10 postinoculation, splenocytes or isolated lung cells were
restimulated with LVS-infected B6-CD45.1 antigen-presenting cells for 24 h. Brefeldin A was added during the last 4 h of coculture. To determine relative mean
fluorescence intensity (MFI), the MFI of the IL-17A-negative population was subtracted from the MFI of the IL-17A-positive population (n 	 4 to 9
mice/group). Data are combined from at least 4 independent experiments. Statistical significance was determined by using an ANOVA with Tukey’s posttest. (A)
Number of IL-17A-producing CD4 cells in the spleen on day 7 postinoculation. (B) Number of IL-17A-producing CD4 cells in the spleen on day 10
postinoculation. (C) Number of IL-17A-producing CD4 cells in the lung on day 7 postinoculation. (D) Number of IL-17A-producing CD4 cells in the lung
on day 10 postinoculation. (E) IL-17A MFI for CD4 T cells in the spleen at 7 days postinoculation. (F) IL-17A MFI for CD4 T cells in the spleen at 10
days postinoculation. (G) IL-17A MFI for CD4 T cells in the lung at 7 days postinoculation. (H) IL-17A MFI for CD4 T cells in the lung at 10 days
postinoculation. (I) Representative histograms of the IL-17A CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in the spleen
on day 7 postinoculation. (J) Representative histograms of the IL-17A CD4 T cells from LVS (solid line)- and LVS clpB (dotted line)-infected mice in
the spleen on day 10 postinoculation. (K) Representative histograms of the IL-17A CD4 T cells from LVS (solid line)- and LVS clpB (dotted
line)-infected mice in the lung on day 7 postinoculation. (L) Representative histograms of the IL-17A CD4 T cells from LVS (solid line)- and LVS clpB
(dotted line)-infected mice in the lung on day 10 postinoculation.
F. tularensis clpB Induces an Altered Immune Response
June 2013 Volume 81 Number 6 iai.asm.org 2039
antigen-specific T cells decreases over time, we hypothesize that
the increased bacterial burdens seen upon challenge 120 days after
vaccination were due to fewer responding T cells than those at day
28. However, we cannot directly address this hypothesis by quan-
tifying the number of Francisella-specific T cells because major
histocompatibility complex class I (MHCI) or MHCII tetramer is
not yet available. Previous LVS clpB infection did not provide
complete protection against aerosolized SchuS4 administered 28
days after LVS clpB infection. LVS clpB infection did, however,
increase the median survival time. One mouse previously inocu-
lated with LVS dotU survived lethal LVS challenge; however, we
do not know if this was the result of a secondary immune re-
sponse. This result was surprising given that our intracellular cy-
tokine staining showed that LVS dotU-infected mice behaved
much like naïve mice, with similar low numbers of IFN--pro-
ducing T cells. However, LVS dotU persisted intracellularly in
some mice until at least day 7 postinoculation, allowing time for a
F. tularensis-specific T cell response to be primed. The protection
was incomplete and indicates that a LVS dotU mutant would not
be an effective vaccine. Overall, our LVS clpB strain was attenuated
in pneumonic tularemia while providing 100% protection against
subsequent lethal infection, just as other groups have shown by
using other models of tularemia (23–25).
After confirming the attenuation of LVS clpB in pneumonic
tularemia, we examined the innate immune response in the lung.
LVS infection does not elicit a proinflammatory cytokine response
in the lung despite promoting phenotypic maturation of dendritic
cells (11). We also found that LVS infection did not elicit a proin-
flammatory cytokine response in the lung despite very high bac-
terial burdens on day 3 postinoculation. LVS clpB, in contrast, did
elicit a robust proinflammatory cytokine response in the lungs of
both B6 and BALB/c mice. The failure of LVS clpB to inhibit early
cytokine production could explain why lower inoculation doses
resulted in poor dissemination to the spleen and liver. Because
antibody depletion of IFN- increased lung LVS clpB burdens,
these data suggest that the high concentrations of proinflamma-
tory cytokines and chemokines in the lung are responsible for the
decrease in bacterial burdens compared to LVS burdens that we
observed on day 3 postinoculation.
Despite a robust proinflammatory innate immune response to
LVS clpB, the innate response was not sufficient to mediate bacte-
rial clearance alone. Additionally, we knew from our protection
studies that there was priming of the adaptive immune response
because mice previously infected with LVS clpB were protected
from lethal LVS challenge. We then began to characterize the
adaptive immune response to LVS clpB. When overall immune
expansion was compared, LVS and LVS clpB infection led to a
similar increase in the number of cells found in the spleen on days
7 and 10. We found a significant decrease in the number of cells
isolated from the lungs of LVS clpB-infected mice on days 7 and 10
postinoculation compared to LVS-infected mice. This decrease
was likely due to contraction of the immune response, as LVS clpB
was rapidly cleared from the host, while LVS-infected mice main-
tained high bacterial burdens. To further support this, the per-
centages of CD4 and CD8 T cells in the lungs were the same in
LVS- and LVS clpB-infected mice, indicating that while the mag-
nitude of the response was changing, the composition of the re-
sponse remained unchanged. When we examined the effector
function of cells in the spleen, we found equivalent numbers of
CD4 and CD8 T cells producing IFN- in LVS- and LVS clpB-
infected mice. The absolute number of CD4 and CD8 T cells in
the lung of LVS clpB-infected mice was decreased compared to
that in lungs of LVS-infected mice, but the percentage of cells
producing IFN- remained the same.
Although we found similar frequencies of IFN--producing
CD4 and CD8 T cells after LVS or LVS clpB infection, we did
find altered expression levels of IFN-, as measured by MFI.
There was a significant increase in the amount of IFN- expressed
by T cells from LVS clpB-infected mice compared to LVS-infected
mice in both the spleen and lung, as measured by MFI. Since
IFN- is critical for LVS clearance, and administration of recom-
binant IFN- decreased bacterial burdens, the increased produc-
tion of IFN- by T cells in LVS clpB-infected mice is consistent
with faster clearance of LVS clpB (18).
The IL-17 response is also important during pneumonic tula-
remia. We have previously shown that LVS intranasal, but not
intradermal, inoculation induces Th17 cells in the lung (19). IL-17
production following F. tularensis infection has been shown to
promote IL-12 production by dendritic cells and to indirectly pro-
mote a Th1 immune response (20). Although infection with LVS
or LVS clpB led to similar numbers of Th17 cells in the lungs of
infected mice, Th17 cells from LVS clpB-infected mice expressed
significantly more IL-17A, as measured by MFI. The increase in
IL-17 expression by LVS clpB-infected mice is consistent with
findings reported previously by Lin et al., where the Th1 response
was promoted by IL-17 (20).
We also measured IFN- and IL-17 concentrations in the
BALF at 7 and 10 days postinoculation. We did not detect in-
creased concentrations of either cytokine in BALF from LVS clpB-
infected mice compared to LVS-infected mice. Although these
data are not in agreement with the flow MFI data, we attribute
the difference to differential distribution of immune cells between
the airspace and lung parenchyma. Cytokines in the BALF are
secreted predominantly by cells within the airspace and represent
production by a variety of immune cells. In contrast, our intracel-
lular cytokine staining experiments measured IFN- and IL-17 in
the entire lung, but this analysis was limited to T cells only. When
we enriched CD4 T cells from the lung and spleen on day 10
postinoculation and restimulated them ex vivo with LVS-infected
T cell-depleted splenocytes, we did not detect differences in IFN-
or IL-17A secretion into the culture supernatant. Differences be-
tween the readout of the flow cytometry analysis and ELISAs could
also account for disparate results. At a minimum, however, CD4
T cells isolated from LVS clpB-infected mice are able to produce
equivalent amounts of cytokine compared to T cells from LVS-
infected mice.
The increase in IFN- production by T cells in LVS clpB-in-
fected mice could be caused by differences in lung prostaglandin
E2 (PGE2) concentrations. PGE2 suppresses IFN- production by
T cells in LVS-infected mice (19). U112 clpB fails to induce PGE2
in BMDMs (35), and LVS clpB induced significantly less PGE2
than did wild-type LVS in BMDMs (data not shown). LVS clpB-
infected mice had significantly lower PGE2 concentrations in the
lavage fluid on days 7 and 10 postinoculation than did LVS-in-
fected mice (data not shown). The high concentration of PGE2 in
LVS-infected mice decreased IFN- production by responding T
cells, an inhibitory process not present in LVS clpB-infected mice.
The increased IFN- production in LVS clpB-infected mice is also
consistent with increased IL-17 expression by T cells in LVS clpB-
infected mice based on the finding by Lin et al. that the Th1 re-
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sponse was promoted by IL-17 (20). However, PGE2 has been
shown to promote IL-23 production, which drives the develop-
ment of Th17 cells (39–42). In LVS clpB-infected mice, there was
little PGE2 present in the BALF, suggesting that there is another
mechanism driving Th17 accumulation, since this cell subset was
present in equivalent numbers in LVS- and LVS clpB-infected
mice despite dramatic differences in PGE2 levels.
Although we are still in the process of identifying the F. tular-
ensis effector molecule responsible for inducing PGE2, it seems
unlikely that ClpB directly induces PGE2. ClpB is an intracellular
chaperone protein that is unlikely to be sensed by the host. A
previous proteomic analysis by Meibom et al. of a membrane-
enriched protein fraction from a LVS clpB mutant identified 5
proteins with decreased expression levels compared to LVS under
conditions of elevated temperature (23). None of the identified
targets of ClpB are required for PGE2 induction (35); therefore,
ClpB must have another target that is involved in PGE2 induction.
We speculate that clpB was identified as a gene necessary for PGE2
induction because ClpB plays a role in assembly of the type VI
secretion system that is responsible for secreting the unknown
PGE2 inducer. Studies to identify the mechanism(s) utilized by F.
tularensis to induce PGE2 synthesis are ongoing.
ClpB is a highly conserved chaperone protein present not only
in prokaryotes but also in eukaryotes and plants (43). Due to
ClpB’s conserved nature and the finding that disruption of clpB
attenuates F. tularensis as well as other bacteria (44–48), this gene
is an excellent candidate target for attenuation of pathogenic bac-
teria for vaccine development. In the case of F. tularensis, LVS clpB
infection was cleared faster than LVS yet induced a robust IFN--
mediated immune response that was protective in both short- and
long-term secondary infections. Therefore, clpB serves as an ad-
vantageous target for F. tularensis attenuation for future vaccine
development. This work also highlights the importance of exam-
ining the immune response to attenuated mutants, particularly in
the course of vaccine development.
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